BIODELPHIS Therapeutics is a Swiss biotech startup developing Antibody-Peptide Inhibitor Conjugates (APIC), a next-generation drug modality targeting proteases with improved precision and reduced toxicity.
Location: Switzerland
Total raised: $190.76K
Investors 1
| Date | Name | Website |
| 27.03.2026 | Venture Ki... | venturekic... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.05.2026 | Seed | $190.76K | Venture Ki... |
Mentions in press and media 2
| Date | Title | Description |
| 22.05.2026 | Biodelphis Therapeutics receives CHF 150,000 from Venture Kick to advance targeted therapies for difficult-to-treat cancers | Current therapies often show limited effectiveness against solid tumors such as pancreatic and lung cancer, particularly in advanced or treatment-resistant cases. New therapeutic strategies are urgently needed, but many biological targets i... |
| 04.05.2026 | Strategic Investments to advance Biodelphis Therapeutics Development | This collaboration combines HAS Group long‑standing expertise in complex bioconjugation, process development, and clinical‑grade manufacturing with Biodelphis Therapeutics’ pioneering APIC platform, a novel drug modality engineered to deli... |